



Press Release

Thursday , May 13 , 2010

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

**STRIDES ARCOLAB ANNOUNCES US FDA APPROVAL OF
VECURONIUM BROMIDE FOR INJECTION
EIGHTH STERILE INJECTABLE APPROVAL IN 2010**


Strides Arcolab Limited (Strides) today announced that the U.S. Food and Drug Administration had granted approval of Vecuronium Bromide for Injection, 10mg per vial and 20 mg per vial (Vecuronium), a neuromuscular blocking agent of intermediate duration is used as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Vecuronium will be offered as 10mg and 20 mg, AP-rated, sterile nonpyrogenic freeze-dried product in packages of ten. The total 2009 U.S. market for injectable Vecuronium is approximated \$10 million, according to IMS data. Launch is expected in the near future.

Vecuronium will be launched under the partnership between Strides and Akorn Inc wherein Strides is developing and supplying 22 injectable products for the U.S. market which will be marketed by Akorn Inc for Akorn-Strides, LLC, a Joint Venture between Strides and Akorn Inc.

About Vecuronium Bromide for injection, USP

Vecuronium is a nondepolarizing neuromuscular blocking agent possessing all of the characteristic pharmacological actions of this class of drugs (curariform). Vecuronium is about 1/3 more potent than Pancuronium ; the duration of neuromuscular blockade produced by Vecuronium is shorter than that of Pancuronium at initially equipotent doses. The time to onset of paralysis decreases and the duration of maximum effect increases with increasing Vecuronium doses.



Vecuronium bromide is contraindicated in patients known to have a hypersensitivity to it. In patients who are known to have myasthenia gravis or the myasthenic (Eaton-Lambert) syndrome, small doses of vecuronium may have profound effects.

About Strides Arcolab Limited:

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

Mr. Ravi Seth CEO – International Operations Ph: +91 80 6658 0121	Mr. Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: maheshn@corvoshandwick.co.in
Mr. N Kannan, Company Secretary (Investors) Tel : +91 80 6658 0751	Ms. Kasturi Wasmatar, Corporate Voice/ Weber Shandwick Mobile: +91 99167 28393 Email: kasturi@corvoshandwick.co.in
Ms. Melissa Arulappan (Media) Tel: +91 98450 22389	

